Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Woodline Partners LP

Woodline Partners LP raised its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 36.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 408,441 shares of the company's stock after acquiring an additional 109,872 shares during the quarter. Woodline Partners LP owned approximately 0.84% of Axsome Therapeutics worth $34,558,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. BVF Inc. IL raised its stake in Axsome Therapeutics by 32.7% in the 4th quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock valued at $117,444,000 after purchasing an additional 342,064 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Axsome Therapeutics by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 912,538 shares of the company's stock worth $77,228,000 after buying an additional 4,079 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Axsome Therapeutics by 10.8% during the fourth quarter. Invesco Ltd. now owns 692,464 shares of the company's stock worth $58,589,000 after buying an additional 67,285 shares in the last quarter. Hood River Capital Management LLC raised its position in shares of Axsome Therapeutics by 3.2% in the fourth quarter. Hood River Capital Management LLC now owns 644,785 shares of the company's stock valued at $54,555,000 after buying an additional 19,701 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its stake in shares of Axsome Therapeutics by 525.7% during the fourth quarter. Lazard Asset Management LLC now owns 537,669 shares of the company's stock valued at $45,492,000 after buying an additional 451,737 shares during the period. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AXSM has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $153.00 target price on shares of Axsome Therapeutics in a research note on Tuesday, April 1st. Truist Financial upped their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Mizuho increased their price objective on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a report on Thursday, March 27th. Jefferies Financial Group began coverage on shares of Axsome Therapeutics in a research report on Monday, April 7th. They issued a "buy" rating and a $200.00 target price on the stock. Finally, Cantor Fitzgerald upgraded shares of Axsome Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $172.14.

Axsome Therapeutics Stock Up 0.7%

Shares of NASDAQ:AXSM traded up $0.72 during midday trading on Monday, hitting $105.07. 467,579 shares of the company's stock traded hands, compared to its average volume of 689,220. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The company has a market cap of $5.17 billion, a PE ratio of -17.54 and a beta of 0.46. The firm's fifty day moving average price is $108.86 and its two-hundred day moving average price is $105.89. Axsome Therapeutics, Inc. has a twelve month low of $64.11 and a twelve month high of $139.13.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, Director Mark Coleman sold 3,000 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $107.49, for a total transaction of $322,470.00. Following the transaction, the director now owns 54,137 shares in the company, valued at $5,819,186.13. The trade was a 5.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.30% of the stock is owned by insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.